echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chengdu Beite Calcium Gluconate Injection passed the consistency evaluation of generic drugs

    Chengdu Beite Calcium Gluconate Injection passed the consistency evaluation of generic drugs

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
    .
    Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020

    .
     
     
      Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
    It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism

    .
     
      According to data from Minet.
    com, in 2020, the
    sales of terminal calcium gluconate injection in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
    20%

    .
     
      Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
    In 2016, the market share was only 0.
    04%, and in the first half of 2021, it has risen to 17.
    38%

    .
     
      At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
    .
     
      The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
    , Ltd.
    took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share

    .
     
      Data source: Minet database, CDE
      On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
    .
    Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020

    .
     
     
      Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
    It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism

    .
     
      According to data from Minet.
    com, in 2020, the
    sales of terminal calcium gluconate injection in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
    20%

    .
     
      Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
    In 2016, the market share was only 0.
    04%, and in the first half of 2021, it has risen to 17.
    38%

    .
     
      At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
    .
     
      The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
    , Ltd.
    took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share

    .
     
      Data source: Minet database, CDE
      On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
    .
    Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020

    .
     
     
      Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
    It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism

    .
     
      According to data from Minet.
    com, in 2020, the
    sales of terminal calcium gluconate injection in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
    20%

    .
    hospital hospital hospital
     
      Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
    In 2016, the market share was only 0.
    04%, and in the first half of 2021, it has risen to 17.
    38%

    .
     
      At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
    .
    enterprise enterprise enterprise
     
      The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
    , Ltd.
    took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share

    .
     
      Data source: Minet database, CDE
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.